JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next
Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, a cancer drug developer, on Monday. The company said it expects about $0.20 in adjusted EPS dilution, split between the fourth quarter and 2026. JNJ shares ended down 0.02% at $207.56. Investors await the Jan. 21 earnings call for 2026 guidance.